Clinical trial · Interventional
A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their Body
A Phase 1 Study of LY3009120 in Patients With Advanced or Metastatic Cancer
NCT02014116CI-TRIAL-00042495terminatedPhase 1Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): This trial was terminated early based on the lack of sufficient clinical efficacy observed.
Summary
Brief summary (as posted)
The main purpose of this study is to see how safe the investigational drug known as LY3009120 is and whether it will work to help people with advanced cancer or cancer that has spread to other parts of the body.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Non-Small-Cell Lung | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
| Colorectal Neoplasms | Colorectal Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Melanoma | Melanoma | ONTOLOGY_EXACT | 0.98 |
| Neoplasm Metastasis | — | UNRESOLVED | — |
| Neoplasms | Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| LY3009120 capsule | Drug | Pan-RAF Inhibitor LY3009120 | ALIAS |
Design
Arms and outcomes
Arms (9)
- type
- EXPERIMENTAL
- label
- Cohort 1 Dose Escalation
- description
- LY3009120 50 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met.
- interventionNames
- Drug: LY3009120 capsule
- type
- EXPERIMENTAL
- label
- Cohort 2 Dose Escalation
- description
- LY3009120 100 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met.
- interventionNames
- Drug: LY3009120 capsule
- type
- EXPERIMENTAL
- label
- Cohort 3 Dose Escalation
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Advanced or metastatic cancer * Other available therapies have failed to cure the cancer * The cancer that has no proven effective therapy * The cancer can be biopsied (depending on the tumor type and/or the dose of drug received, tumor biopsies may be required) * Able to swallow capsules Exclusion Criteria: * Have active cancer in the brain or spinal cord * Have an active infection of any kind (fungal, viral, or bacterial) * Have a cancer of the blood * Are pregnant or breastfeeding * Have some types of eye problems or impairments
References
Publications (0)
Data not yet available
No reference posted for this study.